Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, amifampridine (Firdapse®) cannot be endorsed for use within NHS Wales for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). |
||
|
||
Medicine details |
||
| Medicine name | amifampridine (Firdapse®) | |
| Formulation | 10 mg tablet | |
| Reference number | 640 | |
| Indication | Symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) |
|
| Company | BioMarin Europe Ltd | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 22/03/2010 | |